What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
Portfolio Pulse from Benzinga Insights
4D Molecular Therapeutics (NASDAQ:FDMT) has received diverse analyst ratings over the past quarter, with a recent shift towards a more bullish outlook. The latest ratings include one bullish and three somewhat bullish, with an average 12-month price target of $52.75, marking a significant increase from the previous $37.50. Analysts from Goldman Sachs, BMO Capital, and RBC Capital have adjusted their price targets and ratings, reflecting optimism about the company's future performance. 4D Molecular Therapeutics, a clinical-stage gene therapy company, has shown impressive revenue growth and financial performance, with a notable market capitalization, revenue growth rate of 3940.8%, and strong profitability indicators such as net margin, ROE, and ROA.
February 07, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
4D Molecular Therapeutics has seen a positive shift in analyst ratings, with an increased average price target of $52.75, indicating strong confidence in its future performance. The company's significant revenue growth and solid financial metrics further support this optimistic outlook.
The increase in the average price target to $52.75 from $37.50, along with the company's impressive financial performance and revenue growth, suggests a strong bullish sentiment among analysts. This, combined with the company's advancements in gene therapy, positions FDMT for potential short-term gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100